Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive ...

While it is clear that men with lower urinary ... inability to differentiate between symptoms attributable to detrusor overactivity (DO) and those caused by bladder-outlet obstruction (BOO ...

An overactive bladder may be temporary or become a chronic condition. How long the symptoms last may depend on factors like the underlying cause and treatment adherence. Some conditions may cause ...

Discover how cold weather can trigger prostate problems in men over 60, including frequent urination, hormonal changes, and ...

Gemtesa is approved for men with overactive bladder symptoms who are receiving pharmacologic treatment for benign prostatic hyperplasia.

The FDA has approved Gemtesa® for men with overactive bladder symptoms receiving pharmacological therapy for BPH.

Urination problems affect millions of men worldwide, often developing so gradually that many dismiss early warning signs.

The Food and Drug Administration (FDA) has approved Gemtesa ® (vibegron) for the treatment of overactive bladder (OAB ... milestone for the men with unresolved symptoms of OAB while being ...

It's a CR Best Buy because it has a lower risk of side effects. You might not even have an overactive bladder. Symptoms that are associated with diabetes, kidney stones, multiple sclerosis ...

Imbrium Therapeutics L.P. ("Imbrium"), a subsidiary of Purdue Pharma L.P. ("Purdue"), announced results from a Phase 1b clinical signal detection study evaluating the safety and efficacy of the novel ...

This sham was used in the placebo arm of the Study of Urgent PC vs Sham Effectiveness in Treatment of Overactive Bladder Symptoms (SUmiT) trial. This was a multicenter, placebo controlled ...